GlassScriptPhysician profile
Andrew Wieging
NPI 1689104242
$10,272.43
in general payments reported to CMS, 2019-2025
33 companies · $2,729 in 2025
The $2,729 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $401 · 2021: $1,793 · 2022: $1,467 · 2023: $1,610 · 2024: $2,273 · 2025: $2,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,545 · Education: $66.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,545.37 |
| Education | $66.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,306.25 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,434.20 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $892.99 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $846.05 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $826.97 | 2021-2025 | Jardiance, Stiolto Respimat |
| Axsome Therapeutics, INC. | $419.96 | 2023-2025 | Auvelity |
| Amgen INC. | $397.16 | 2020-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $315.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.30 | 2025 | Caplyta |
| Astellas Pharma US INC | $307.66 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $303.84 | 2021-2025 | Trelegy Ellipta |
| Pfizer INC. | $243.53 | 2020-2025 | |
| Vanda Pharmaceuticals INC. | $203.34 | 2025 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $198.88 | 2020-2021 | |
| Exact Sciences Corporation | $188.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $170.12 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $169.82 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.49 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $98.40 | 2021 | |
| Sumitomo Pharma America, INC. | $89.55 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $85.90 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $50.95 | 2021-2023 | Xarelto |
| Corcept Therapeutics | $42.93 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $40.15 | 2021-2023 | Unithroid |
| Insulet Corporation | $38.98 | 2021 | |
| Eisai INC. | $32.29 | 2021 | |
| Medtronic, INC. | $29.97 | 2025 | Inceptiv |
| Phathom Pharmaceuticals, INC. | $19.34 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.97 | 2022 | |
| Esperion Therapeutics, INC. | $14.27 | 2020 | |
| Horizon Therapeutics Plc | $14.24 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.14 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wieging listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.